Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics NASDAQ: CRSP is preparing to advance several experimental treatments toward late-stage trials, with executives pointing to upcoming data from its cardiovascular and cell therapy programs and growing demand for its commercial product, CASGEVY.
Crispr Therapeutics remains a market leader in gene-editing, with Casgevy and a robust pipeline targeting hematology, cardiovascular, autoimmune, and regenerative medicine. CRSP's revenue growth from Casgevy has been slower than anticipated, but operational momentum and expanded patient access are improving the long-term outlook. Early-stage data for CTX310 in cardiovascular disease show promising, durable efficacy and safety, positioning CRSP ahead of competitors in gene-editing therapies.
ZUG, Switzerland and BOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Tuesday, November 17, 2026 at 10:00 a.m. GMT. A live webcast of the fireside chat will be available on the “Events & Presentations” page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events.
-Data presented in a late-breaking oral presentation at AHA- -A single-course treatment with CTX310 produced a mean reduction from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides (TG) at Day 30 in patients with severe hypertriglyceridemia (sHTG), who had a median baseline TG level above 1,000 mg/dL- -CTX310 was well tolerated, with no treatment-related serious adverse events and no clinically relevant elevations in liver transaminases- ZUG, Switzerland and BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today presented clinical data from its Phase 1b clinical trial evaluating CTX310®, an investigational, in vivo CRISPR/Cas9 gene editing therapy targeting angiopoietin-like protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia (sHTG). A single-course treatment with CTX310 produced mean reductions from baseline at Day 30 of 65% in circulating ANGPTL3 and 63% in triglycerides (TG) in participants with a median baseline TG level above 1,000 mg/dL.
Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all responders maintaining response
ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase 1/2 trial of zugocabtagene geleucel (zugo-cel), its investigational allogeneic CRISPR/Cas9 gene-edited chimeric antigen receptor (CAR) T cell therapy targeting CD19, will be presented in an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12 to 15, 2026.
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to a loss of $1.17 per share a year ago.